Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 381

1.

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains.

Stuhlmiller TJ, Miller SM, Johnson GL.

Mol Cell Oncol. 2015 Jun 10;3(1):e1052182. doi: 10.1080/23723556.2015.1052182. eCollection 2016 Jan.

2.

Targeting the breast cancer kinome.

Miller SM, Goulet DR, Johnson GL.

J Cell Physiol. 2016 May 17. doi: 10.1002/jcp.25427. [Epub ahead of print]

PMID:
27186656
3.

Weight loss reduces basal-like breast cancer through kinome reprogramming.

Qin Y, Sundaram S, Essaid L, Chen X, Miller SM, Yan F, Darr DB, Galanko JA, Montgomery SA, Major MB, Johnson GL, Troester MA, Makowski L.

Cancer Cell Int. 2016 Apr 1;16:26. doi: 10.1186/s12935-016-0300-y. eCollection 2016.

4.

Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.

Ahmad S, Johnson GL, Scott JE.

Biochem Biophys Res Commun. 2015 Aug 7;463(4):888-93. doi: 10.1016/j.bbrc.2015.06.029. Epub 2015 Jun 6.

PMID:
26056008
5.

Aspergillus-Specific Lateral-Flow Device and Real-Time PCR Testing of Bronchoalveolar Lavage Fluid: a Combination Biomarker Approach for Clinical Diagnosis of Invasive Pulmonary Aspergillosis.

Johnson GL, Sarker SJ, Nannini F, Ferrini A, Taylor E, Lass-Flörl C, Mutschlechner W, Bustin SA, Agrawal SG.

J Clin Microbiol. 2015 Jul;53(7):2103-8. doi: 10.1128/JCM.00110-15. Epub 2015 Apr 22.

6.

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL.

Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9.

7.
8.

Insufficient demonstration of long-term stability of Aspergillus galactomannan.

Johnson GL, Sarker SJ, Bustin SA, Agrawal SG.

J Clin Microbiol. 2014 Nov;52(11):4118. doi: 10.1128/JCM.02342-14. No abstract available.

9.

MEK inhibition in non-small cell lung cancer.

Stinchcombe TE, Johnson GL.

Lung Cancer. 2014 Nov;86(2):121-5. doi: 10.1016/j.lungcan.2014.09.005. Epub 2014 Sep 16. Review.

10.

Assessing adaptation of the cancer kinome in response to targeted therapies.

Zawistowski JS, Graves LM, Johnson GL.

Biochem Soc Trans. 2014 Aug;42(4):765-9. doi: 10.1042/BST20130274. Review.

11.

Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.

Tarpley M, Abdissa TT, Johnson GL, Scott JE.

Anticancer Res. 2014 Apr;34(4):1629-35.

12.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

13.

An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation.

Turowec JP, Zukowski SA, Knight JD, Smalley DM, Graves LM, Johnson GL, Li SS, Lajoie GA, Litchfield DW.

Mol Cell Proteomics. 2014 May;13(5):1184-97. doi: 10.1074/mcp.M113.037374. Epub 2014 Feb 20.

14.

Adaptive reprogramming of the breast cancer kinome.

Stuhlmiller TJ, Earp HS, Johnson GL.

Clin Pharmacol Ther. 2014 Apr;95(4):413-5. doi: 10.1038/clpt.2014.8. Epub 2014 Jan 10. Review.

15.

MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis.

Pham TT, Angus SP, Johnson GL.

Genes Cancer. 2013 Nov;4(11-12):419-26. doi: 10.1177/1947601913513950.

16.

Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling.

Wu C, Haynes EM, Asokan SB, Simon JM, Sharpless NE, Baldwin AS, Davis IJ, Johnson GL, Bear JE.

J Cell Biol. 2013 Dec 23;203(6):907-16.

17.

UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, Janzen WP, Johnson GL, Wang X, Frye SV, Earp HS 3rd, Graham DK.

Mol Cancer Ther. 2013 Nov;12(11):2367-77. doi: 10.1158/1535-7163.MCT-13-0040. Epub 2013 Aug 30.

18.

Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.

Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, Johnson GL, Baldwin AS, Graves LM.

PLoS One. 2013 Jun 24;8(6):e66755. doi: 10.1371/journal.pone.0066755. Print 2013.

19.

Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects on Androgen Dependent and Androgen Independent Prostate Cancer Cells.

Samykutty A, Shetty AV, Dakshinamoorthy G, Bartik MM, Johnson GL, Webb B, Zheng G, Chen A, Kalyanasundaram R, Munirathinam G.

PLoS One. 2013 Jun 18;8(6):e65889. doi: 10.1371/journal.pone.0065889. Print 2013.

20.

Significant decline in Galactomannan Signal during storage of clinical serum samples.

Johnson GL, Sarker SJ, Hill K, Tsitsikas DA, Morin A, Bustin SA, Agrawal SG.

Int J Mol Sci. 2013 Jun 24;14(7):12970-7. doi: 10.3390/ijms140712970.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk